Skip to main content

Advertisement

Table 1 The current observed population receiving MEP

From: The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials

   SD or percentage
Number of patients 65
Female/Male 29/36 45% female
Age range 19–84
Age mean 56 ±11.5
Current smoker 17 26%
Duration of asthma (years) 18.2 ± 14.4
Historical eosinophilic count 1046 ± 885
Blood eosinophil count at baseline 653 ±381
Mean exacerbations previous12 months 3.0 ±1.8
Hospitalized patients previous 12 months 20 31%
Mean OCS dose at baseline (mg) 9.2 ±9.2
Mean FEV1 at baseline (%) 73 ±18.1
ACT 16.6 ±4.7
Concomitant nasal polyposis 47 72%